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Purpose: For patients with psoriasis, treatment adherence and persistence are fundamental if 
therapeutic goals are to be met. Patient Support Programs (PSPs) may be used as a support 
tool to assist patients and health care professionals optimize treatment and improve disease 
management.
Patients and Methods: In Italy, the PSP PSOLife CARE, which began on the 9th of 
February 2017 and is ongoing, aimed to support patients with psoriasis under therapy with 
secukinumab (Cosentyx®). A team of medical professionals including Dermatologists, 
Psychologists, Nutritionists, and field Nurses provided outpatient treatment as well as remote 
support via phone calls. Patients had a standard duration in the Program of 6 months. This 
report analyzes the data of patients who benefited from the Program from February 2017 to 
August 2020, for a total observation of 42 months.
Results: We provide here a descriptive report on the benefits of participation in the PSOLife 
CARE Program for patients with psoriasis and medical professionals involved in their care. 
Throughout their time in the PSOLife CARE Program, patient satisfaction remained con-
sistently high with sustained improvements observed in all aspects of quality of life (ie 
emotional, social, physical, and economic). Despite exiting from the Program, most patients 
continued to adhere to secukinumab. Medical professionals also reported positive outcomes 
on their interactions with patients, with more than half of those surveyed rating the overall 
quality of the Program as “Outstanding”.
Conclusion: By supporting treatment adherence, the PSOLife CARE Program may have 
empowered patients to better manage their psoriasis, increasing their satisfaction with 
treatment and quality of life.
Keywords: dermatology, PSOLife CARE Program, quality of life, treatment adherence
Plain Language Summary
● Psoriasis is a chronic, immune-mediated, inflammatory skin condition characterized by 
red, scaly patches with symptoms of itching, burning, and pain. For people with 
psoriasis, the condition can be debilitating and severely affect everyday living, causing 
a considerable burden.
○ Biological therapies, which target specific components of the immune system, are 
very effective treatments for psoriasis. However, adherence to and persistence with 
prescribed therapies are fundamental if therapeutic goals are to be met.
● To improve treatment adherence, pharmaceutical companies may offer Patient Support 
Programs to augment therapeutic strategies and improve patient outcomes through 
better disease management.
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○ The Italian PSOLife CARE Patient Support Program provided in-person and remote 
support for patients with psoriasis under therapy with secukinumab (known as 
Cosentyx®) through a dedicated team of Dermatologists, Psychologists, 
Nutritionists, and field Nurses.
● Throughout the PSOLife CARE Program, patient satisfaction remained consistently 
high with sustained improvements observed in all aspects of daily life.
○ Most people who took part in the PSOLife CARE Program continued treatment with 
secukinumab despite exiting from the Program.
○ Health care professionals also felt supported and reported positive outcomes with 
their patients.
● Overall, the PSOLife CARE Program improved adherence to secukinumab, increasing 
treatment satisfaction. Ideally, this should motivate patients to better manage their 
psoriasis leading to them having a more positive outlook of their condition and 
therapeutic regimen.
Introduction
Psoriasis is a chronic, immune-mediated, inflammatory skin disease affecting 
2% to 4% of the Western population.1 Its pathophysiology is complex and 
associated with the dysregulation of the immune system. In Italy, the reported 
prevalence of psoriasis has been estimated at 1.8% to 3.1%, with high variability 
(from 0.8% to 4.5%) across the regions.2–4 In 2010, an incidence rate of 2.30 to 
3.21 cases per 1000 person-years was calculated from an Italian study cohort of 
511,532 adults who had received a first-ever diagnosis of psoriasis from 2001 to 
2005.5
The clinical manifestations of psoriasis vary between individuals. Plaque psor-
iasis is the most common form, typically presenting as well-defined, scaly erythe-
matous patches or plaques, and occurring in 85% to 90% of affected patients.1 
Symptoms of psoriasis include itching, burning, and pain. Psoriasis is commonly 
associated with physical and psychological comorbidities, which, together with 
symptoms, can negatively affect quality of life and work productivity causing 
considerable burden to the patient.6
Patients with mild-to-moderate psoriasis can be treated with topical agents 
such as glucocorticoids, vitamin D analogs, and phototherapy; patients with 
moderate-to-severe psoriasis may require conventional or biologic systemic 
treatments.7 Novel biologic therapies, which target specific inflammatory path-
ways including the tumor necrosis factor-α signaling pathway and the interleu-
kin (IL)-23/TH17 axis, have improved treatment outcomes without 
compromising patient safety.8 Secukinumab (Cosentyx®), a fully human mono-
clonal antibody, selectively targets IL-17A and has long-lasting efficacy in the 
treatment of psoriasis as well as a favorable safety profile.9–15 It is approved in 
Europe and the USA for the treatment of moderate-to-severe plaque psoriasis in 
adults who are candidates for systemic therapy at a recommended dose of 300 
mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg 
every 4 weeks thereafter.16,17
If therapeutic goals are to be met for patients with psoriasis, they must adhere 
to the prescribed treatment regimen. However, like all drugs, there is always a 
theme of non-adherence to treatment for various reasons. It could be argued that 
patients with a chronic inflammatory disease such as psoriasis are a more “fragile 
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population” who need greater attention. These “fragile” 
patients may be insecure in the management of self- 
administration of biological drugs due to the need to 
inject the drug (ie, to understand in-depth how the drug 
is administered, how to use the device, and the areas 
where the drug is injected), and who need reminding of 
specialist’s recommendations, follow-up visits, and exam-
inations. In addition, when the lesion has disappeared, 
patients often tend to try to “skip” administration of their 
prescribed treatment regimen, considering themselves 
“healed”. Only the clinician can decide on any change 
or suspension of therapy because, due to the chronic- 
relapsing nature of psoriasis, the disease never heals but 
can be kept under control over time with appropriate 
drugs. Patient Support Programs (PSPs), which assist 
patients and health care professionals to optimize treat-
ment and improve disease management, have increased 
treatment adherence and persistence across a broad range 
of autoimmune diseases including psoriasis.18–20 Indeed 
PSPs, address all the issues mentioned above to ensure 
patients are autonomous, safe, aware, and have improved 
treatment adherence.
The PSP PSOLife CARE, funded by Novartis, 
designed and executed by IQVIA, aimed to support 
patients with psoriasis in Italy under therapy with secuki-
numab. This PSP was implemented at no cost to patients 
or the Italian National Health Services. The PSOLife 
CARE Program, which began on the 9th of February 
2017 and is ongoing, provides in-person and remote sup-
port to patients and involves a team of medical profes-
sionals including Dermatologists, Psychologists, 
Nutritionists, and field Nurses.
Herein is a descriptive report on the relationship 
between participation in the PSOLife CARE Program 
and patient satisfaction with treatment, quality of life, 
and treatment adherence, as well as the impact of the 
PSP on the satisfaction and approach of medical profes-




This is a descriptive report of the PSOLife CARE Program 
for secukinumab-treated patients with psoriasis in Italy. 
Clinical Centers distributed throughout Italy were invited 
to take part in the Program and patients were recruited from 
February 2017. This report analyzes the data of patients 
who benefited from the Program from February 2017 to 
August 2020, for a total observation of 42 months. 
Physicians of activated Clinical Centers presented the PSP 
to eligible patients under treatment with secukinumab; 
patients were free to choose whether or not to be enrolled 
in the Program. All data were collected by telephone, 
directly from the patients. The questionnaires used are 
standard, and the data recorded on a dedicated platform. 
All patients gave written informed consent to participate in 
the PSP. Due to the nature of the PSOLife CARE Program, 
ethical approval was not required because it is not a clinical 
study. Instead, PSPs are a category of projects that support 
patients in managing their therapy/pathology. They are not 
defined as clinical studies as their activities do not endorse a 
new drug, observe a phenomenon, or compare different 
patient populations in therapy with different products. 
Instead, PSPs offer services that promote better patient 
adherence to the therapy assigned by their doctor.
PSPs, of course, must comply with the rules on 
Pharmacovigilance and Privacy, with appropriate proce-
dures and forms in place to permit full compliance. For 
the PSOLife CARE, the following is envisaged:
1. The adhesion by the responsible doctor by filling in 
the form and privacy information (with specific, explicit 
purpose: “To carry out anonymous statistical surveys and 
scientific publications”);
2. The doctor, starting from his adhesion, can present 
the PSP to the patients in therapy;
3. Patients can join the PSP by filling in the form and 
privacy information (with specific, explicit purpose: “To 
carry out anonymous statistical surveys and scientific 
publications”);
4. IQVIA collaborators collect documents on the terri-
tory while carrying out the planned activities.
For PSPs, there is no approval flow from the ethics 
committee of each Center, as there is no protocol (or 
similar) to view. Instead, the supporting material merely 
details the type of services provided and available to 
patients. Furthermore, from a “legislative” point of view, 
the only framework that regulates PSPs is the 
Farmaindustria code (Point 4.7), which details the above 
and does not provide any approval flow for the aforemen-
tioned programs.
Data Collection
As this was not a clinical trial, there were no specific 
inclusion or exclusion criteria, except that patients had to 
be affected by psoriasis and treated with secukinumab. 
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Data were collected regarding the number of months 
between the date patients first received secukinumab 
(Therapy start date) and the date patients were enrolled 
in the Program (Program start date) during the different 
Program periods. Therapy administration dates, as 
described below, and the date of therapy discontinuation 
were also collected.
Patients had a duration in the Program of 6 months; 
measurements were also taken at 12 and 24 months for a 
limited number of patients. Figure 1 depicts the Program 
structure through which a patient journeyed showing the 
number of times a patient was surveyed during their time 
in the Program and after their exit from the Program, as 
well as optional visits to medical personnel.
The dates of secukinumab administration were col-
lected during the 6 months of the Program in order to 
assess management of therapy administrations. Data were 
assessed as to whether secukinumab had been adminis-
tered in an acceptable or anomalous range according to the 
recommended dosing schedule (ie 300 mg by subcuta-
neous injection at weeks 0, 1, 2, 3, and 4, followed by 
300 mg every 4 weeks thereafter). For the first 4 weeks in 
the Program, dosing in a range of 0–9 days was considered 
acceptable whereas a range of 10–23 days was considered 
anomalous. Similarly, for dosing every 4 weeks thereafter, 
a range of 24–34 days was considered acceptable and ≥35 
days was considered anomalous.
Patients were treated as outpatients and data on their 
adherence to treatment, quality of life, and the number of 
outpatient visits were collected. Patients were also 
provided with remote support, education, and training via 
phone calls.
At each Clinical Center, patients were overseen by one 
or more of the following medical professionals: 
Dermatologist, Nutritionist, Psychologist, and/or field 
Nurse. The monthly distribution and type (Dermatologic, 
Nutritional, Psychological, or field Nurse) of visits and 
phone calls were recorded.
Questionnaires
Patients were asked to express his/her opinion on their 
overall satisfaction with the PSOLife CARE Program, 
assessed using a score of 1 to 5 (1 – Did not meet my 
expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – 
Very Satisfactory; 5 – Outstanding), and completed a 6- 
question survey detailing their satisfaction (Table 1). This 
survey was designed to assess the quality of the Program 
and of information shared, the usefulness of the Program 
on the management of visits as well as on therapy manage-
ment and pathology management, and whether the patients 
felt the Program should be changed. The patient satisfac-
tion questionnaire was administered twice per patient dur-
ing the Program.
The impact of psoriasis on patients’ quality of life was 
assessed at months 1–6, 12, and 24 using a 4-question 
survey. In this survey, patients were asked to evaluate the 
impact of their psoriasis on the emotional, social, physical, 
and economic aspects of daily life, each with a score 
between 0–100, where “0” means a low impact and 
“100” means a high impact.
Figure 1 PSOLife CARE program structure. 
Abbreviation: QOL, quality of life.
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Medical professionals, with patients who had >6 
months duration in the Program, were invited to complete 
a Satisfaction Questionnaire on the PSOLife CARE 
Program to evaluate the impact of the Program on their 
approach with patients (Table 2).
To assess the usefulness of the Program for ongoing 
adherence to therapy, patients were surveyed at 12 months 
and 24 months (Table 3). In this survey, patients were 
questioned on the long-term impact of the PSP and 
whether they felt the Program had been beneficial for 
their ongoing therapy adherence. Patients were also ques-
tioned as to whether they were still under treatment with 
secukinumab and, if not, were questioned as to why.
The questionnaires used to assess patient satisfaction, 
medical professional satisfaction, the impact of psoriasis 
on patients’ quality of life, and patient adherence to 
Table 1 Patient Satisfaction Questionnaire
Question Response
1). Have you been advised with clear and fully explained information about the services provided within the Program to easily activate them? Score a
2). How do you define the quality of the Program? Score a
3). Do you feel more confident in drug administration and management thanks to this Program? Score a
4). Do you find this Program helpful in following the Clinical Centre’s recommendations? Score a
5). Do you feel supported by this Program in dealing with the management of your psoriasis? Score a
6). Do you think the Program should be changed in some way? Yes/No
Notes: a1 – Did not meet my expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – Very Satisfactory; 5 – Outstanding.
Table 2 Medical Professional Satisfaction Questionnaire
Question Response
1). Do you find this Program the most suitable solution to deal with patients in treatment with secukinumab? Score a
2). In which of the following aspects do you feel more supported?
a. Is the patient more followed and aware? Yes/No
b. Are the monitoring visits taking less time? Yes/No
c. Could you get more information about the patients’ disease management? Yes/No
d. Any other relevant aspect? Yes/No
3). If Yes to question 2a, in which aspect do you find the patient more followed and aware?
a. Management of secukinumab %
b. Management of side effects %
c. Management of the dermatological aspect %
d. Management of the psychological aspect %
e. Management of the nutritional aspect %
f. Others %
4). If Yes to question 2b, what is the average time saved at each monitoring visit?
a. <5 minutes %
b. 5–10 minutes %
c. 10–20 minutes %
d. >20 minutes %
5). If Yes to question 2c, which kind of information did you get thanks to the Program?
a. Patient adherence %
b. Compliance with the recommendations %
c. Side effects %
d. Other? If yes, which aspects could you mention? %
6). If Yes to question 2d, which kind of information could you get thanks to the Program in addition to the ones yet mentioned?
7). What is your opinion about the overall quality of the Program? Score a
Notes: a1 – Did not meet my expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – Very Satisfactory; 5 – Outstanding.
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treatment were created specifically for the PSOLife CARE 
Program and have not been validated in other support 
programs.
Data Analysis
Data are presented as whole numbers, cumulative num-
bers, or percentages. Data analysis used a cumulative 
method with a weighted average for the calculation of 
the average satisfaction rate. The data of quality of life 
and secukinumab administration date are aggregated and 
analyzed with average by month of the patient’s stay in the 
program.
Results
Patient Support Program Services
Clinical Centers were distributed throughout Italy with a 
total of 28 active centers. Of these, 6 Clinical Centers 
located in Northern Italy, 5 in Central Italy, and 9 in 
Southern Italy had patients.
The availability of a Dermatologist, Psychologist, 
Nutritionist, or field Nurse varied amongst Centers. 
Except for a center in Central Italy, all Centers had a 
field Nurse. A Dermatologist was present in all Northern 
and Central Centers and 6 of the 9 Centers in Southern 
Italy. A Psychologist was available in 3, 1, and 7 Centers 
in North, Central, and South Italy, respectively; 3 Centers 
in Northern Italy and 2 in Southern Italy had a Nutritionist.
The uptake of patients into the PSOLife CARE 
Program was distributed over 42 months, culminating in 
a total uptake of 525 patients (Figure 2). There was a 
noticeable decrease in the uptake of patients into the 
Program from February 2020.
The average patient age was 51.45 years and 62.4% 
(327/524; this information was not available for 1 patient) 
of the patients were male. The average time period 
between the Therapy start date and Program start date 
ranged from 0.6 months to 5.7 months (Table 4). From 
October 2019 onwards, the average time period between 
Therapy and Program start dates was noticeably less than 
at the start of the Program, which was due to two principal 
reasons. From October 2019, most of the targeted Clinical 
Centers had been activated and, in the first phase (after 
activation), the Clinical Centers already had patients in 
therapy. Therefore, after the start-up phase, the Clinical 
Table 3 Patient Adherence Questionnaire
Question Response
1. After some time out of the Program, in which of the following aspects do you think the PSOLife Program’s calls have been helpful?
a. Therapy Adherence %
b. Organization/Reminder of the visits %
c. Emotional Support %
2. How do you consider/assess your therapy adherence since you are no longer under the Program?
a. Excellent (>95%) %
b. Good (>80% to <95%) %
c. Low (<80%) %
3. Are you still under treatment with secukinumab? Yes/No
4. If No, specify the motivation
a. Not needed %
b. Switch to a similar biologic drug %
c. Change of therapy %
Table 4 Average Time Period in Months Between the Date 
Patients First Received Secukinumab (Therapy Start Date) and the 





April 2017–September 2017 5.7 69
October 2017–March 2018 3.4 108
April 2018–September 2018 4.2 79
October 2018–March 2019 5.3 133
April 2019–September 2019 3.4 75
October 2019–March 2020 0.7 39
April 2020–September 2020 0.6 9
Notes: aData was calculated on 512 patients as this data was not available for 13 patients.
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Centers proposed the program nearer to the prescription 
date.
Throughout the 42-month Program >1300 specialist 
sessions were executed, including 1135 outpatient visits 
to a Dermatologist, 188 visits to a Psychologist, 53 visits 
by a field Nurse, and 18 visits to a Nutritionist. The 
increase in the number of visits was linked to the increase 
in the number of patients enrolling in the Program. 
Patients also received support, education, and training via 
phone calls, with a total of 6934 remote sessions 
implemented.
During the Program, 3340 administrations of secuki-
numab were recorded. Of these, 3066 (92%) were admi-
nistered in an acceptable range (1137 administered 
between 0–9 days with an average duration of 7 days, 
and, 1929 administered between 24–34 days with an aver-
age duration of 29 days). Conversely, there were 274 
administrations in an anomalous range (67 administered 
between 10–23 days with an average duration of 18 days, 
and, 207 administered ≥35 days with an average duration 
of 44 days).
Patient Satisfaction
Across the PSOLife CARE Program treatment period, 
patient satisfaction was high with an average score per 
6-month period between 4.0 (“Very satisfactory”) and 4.8 
(almost “Outstanding”) (Figure 3). Patient satisfaction 
with the PSP declined from October 2019 to March 
2020 before recovering from April 2020 to September 
2020.
For the patient satisfaction questionnaire, 680 
responses were collected. Most patients felt they had 
received clear and complete information that allowed 
them to easily activate the Program services, with 29.6% 
(201/680), 8.8% (60/680), and 60.9% (414/680), respec-
tively, of patients rating the Program as “Satisfactory”, 
“Very satisfactory”, and “Outstanding”. When asked 
whether the Program had improved their confidence in 
drug administration and management and whether they 
found the Program helpful in following the recommenda-
tions provided by the Center where they were being trea-
ted, 98.1% of patients (667/680) rated these items as 
“Satisfactory” to “Outstanding”.
Overall, the quality of the Program was rated as “Very 
satisfactory” to “Outstanding” by 86.3% of patients (587/ 
680) and most patients felt supported by the PSOLife CARE 
Program when dealing with the management of their psor-
iasis, with 23.4% (159/680), 14.7% (100/680), and 59.9% 
(407/680) of patients, respectively, rating the Program as 
“Satisfactory”, “Very satisfactory”, and “Outstanding”. 
Only 31 (4.6%) patients stated that the Program should be 
changed in some way, specifically with regards to some of 
the services provided within the Program.
The emotional, social, physical, and economic impact 
of psoriasis on quality of life over a 24-month detection 
period is shown in Figure 4A–D. The impact of psoriasis 
on all four aspects decreased after the first month in the 
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Figure 2 Uptake of patients and Clinical Centers into the PSOLife CARE Program.
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Figure 3 Overall patient satisfaction with the PSOLife CARE Program per treatment period. 
Notes: Satisfaction score: 1 – Did not meet my expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – Very Satisfactory; 5 – Outstanding.
Figure 4 The (A) emotional, (B) social, (C) physical, and (D) economic impact of psoriasis on patients’ quality of life over a 24-month detection period during the PSOLife 
CARE Program.
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PSOLife CARE Program and remained relatively stable 
over time.
Medical Professional Satisfaction
Medical professionals were also surveyed on their satis-
faction with the PSOLife CARE Program and asked to 
evaluate the impact of the Program on their approach with 
patients. Of the 81 medical professionals with patients 
who had >6 months of stay in the Program, 28 
Dermatologists responded. When asked whether they felt 
the Program was supportive in their management of 
patients treated with secukinumab, 25.0% (7/28), 39.3% 
(11/28), and 35.7% (10/28), respectively, of medical pro-
fessionals reported this as being “Satisfactory”, “Very 
satisfactory”, and “Outstanding”.
All medical professionals who responded to the survey 
felt their patients were better monitored and better 
informed of their disease, especially regarding the man-
agement of secukinumab (54%), the dermatological aspect 
(21%), and the psychological aspect (14%) of their psor-
iasis, as well as the side effects associated with secukinu-
mab (11%). The majority of medical professionals (71%) 
felt the monitoring visits were not taking less time, with 
time saved on average at each visit equaling 5–10 minutes, 
4–1 minutes, and 0 minutes, respectively, for 23%, 9%, 
and 68% of medical professionals.
More than half (57%) of medical professionals 
reported that they were able to get more information 
about their patients’ disease management, specifically 
regarding patient adherence (32%) and compliance with 
recommendations (29%). When asked their opinion on the 
overall quality of the Program, 53.6% rated it as 
“Outstanding”, 32.1% as “Very satisfactory”, and 14.3% 
as “Satisfactory”.
Treatment Adherence
Most patients continued to adhere to treatment despite dis-
continuing the Program, with discontinuation of patients 
after 6-months being due to the structure of the Program 
(Figures 5A and E). At 12 months, 51% of patients (n=82) 
considered their therapy adherence to be excellent (>95%), 
42% considered their therapy adherence to be good (>80% to 
<95%), whereas treatment adherence was low (<80%) for 
7% of the patients (Figure 5B); at 24 months (n=182), these 
figures were 57%, 27%, and 16%, respectively (Figure 5F). 
Almost three-quarters of patients (71% and 73%, respec-
tively) continued to receive secukinumab at 12 and 24 
months (Figures 5C and G); the main motivation for 
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Figure 5 Treatment adherence at (A–D) 12 months (n=82) and (E–H) 24 months (n=182).
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treatment discontinuation was that it was no longer needed 
(16% at both 12 and 24 months) (Figures 5D and H).
It should be noted, however, that this survey was 
implemented towards the end of 2019 and therefore after 
the PSP had started. Consequently, we were only able to 
reach some of the patients, which explains why the patient 
numbers are low. We were unable to contact all patients 
after their exit from the Program for the following reasons: 
unavailability of some patients after leaving (no answer to 
telephone calls); some patients were immediately sub-
jected to the questionnaire as they had left the PSP some-
time prior, which explains the higher patient number at 24 
months (n=182) than at 12 months (n=82).
Discussion
Overall, patient satisfaction remained consistently high dur-
ing the PSOLife CARE Program, with sustained improve-
ments observed in all aspects of quality of life (ie 
emotional, social, physical, and economic). Adherence to 
secukinumab continued over the long-term for most patients 
despite exiting from the Program. Medical Professionals 
also reported positive outcomes on their interactions with 
patients, with more than half of those surveyed rating the 
overall quality of the Program as “Outstanding”.
Medication adherence is a key component of a success-
ful treatment regimen. By supporting patient adherence, the 
PSOLife CARE Program may have empowered patients to 
better manage their psoriasis. This is likely to be a direct 
result of the high number of outpatient visits undertaken, 
the majority of which involved a Dermatologist consulta-
tion, and of the remote sessions offering comprehensive 
specialty support, education, and training to patients via 
phone calls.
The PSP captures the patients’ need to be followed 
during the treatment once the specialist dermatologist has 
set the therapy. Personalized support accompanies patients 
over time, making them more solid, autonomous, aware, 
and adherent to treatment. In addition, the PSP PSOLife 
CARE Program has a holistic approach to the patient 
because it offers support on other comorbidities that can 
occur together with psoriasis, for which it is essential to 
have multidisciplinary management of the disease (this is 
the reason for the visits with a psychologist and nutrition-
ist). All this can only have a positive impact on the patient 
and their quality of life in general.
To achieve therapeutic goals in psoriasis, treatment 
adherence and persistence are crucial. Patients in the 
real-world often discontinue treatment due to loss of 
effectiveness or the development of adverse side effects, 
lowering the rates of drug survival compared with clinical 
trials.21–23 Participation in PSPs, such as the PSOLife 
CARE Program, may add significant value to the treatment 
of patients with psoriasis by improving their satisfaction 
with treatment, treatment adherence, and quality of life.
Approximately two-thirds of patients rated the quality of 
the PSOLife CARE Program as “Outstanding” and felt that 
they had received clear and complete information that 
allowed them to easily activate the Program services. 
Importantly, most patients felt that the Program helped 
them to manage and administer secukinumab correctly. 
This has important implications on maintaining adherence 
to treatment over the long-term, with 57% of patients rating 
their adherence as excellent despite having been out of the 
Program for 12 months. In the SCULPTURE Extension 
study, high levels of skin clearance were sustained through 
5 years of treatment with secukinumab and associated with 
improved health-related quality of life in patients with mod-
erate-to-severe psoriasis.9 Hence, improvement in the quality 
and effectiveness of care, and consequently improved con-
fidence in managing their psoriasis, could lead to long-lasting 
skin clearance and a better quality of life for patients.
PSPs support better disease management in chronic 
autoimmune diseases. The HUMIRA Complete PSP, for 
example, provided one-on-one, personal support to 
patients with chronic autoimmune diseases who were 
receiving adalimumab.18–20 Over a 12-month follow-up 
period, participation in the HUMIRA Complete PSP was 
associated with improved adherence and persistence to 
adalimumab, significantly lowering medical costs and 
overall health care costs. In a systematic review of 64 
trials or observational studies of PSPs targeting chronic 
diseases, at least one significant positive clinical outcome 
was reported in 41 (64.1%) studies.24 Whilst a positive 
outcome on adherence was the most commonly reported 
clinical outcome, the review also found positive impacts 
on clinical and humanistic outcomes, including functional 
status and quality of life, as well as reduced health care 
utilization and costs. Consequently, through the use of 
PSPs, pharmaceutical companies can augment therapeutic 
strategies and improve patient outcomes. Health care sys-
tems are also increasingly recognizing the value of PSPs 
due to lowered health care costs.
Limitations
There are limitations to the PSOLife CARE Program that 
must be acknowledged. None of the questionnaires used to 
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assess outcomes were validated, questioning the accuracy 
of their results. The length of the detection period, with a 
standard duration in the Program of only 6 months, may 
not have been long enough for habits to be established as 
routine. As we did not limit data analysis to patients who 
had concluded the PSP by August 2020, and data accumu-
lation is ongoing, some patients may not have completed 
their 6 month stay and therefore represent an “incomplete” 
path. Moreover, the Program was not designed as a clin-
ical, randomized, or observational study and, as such, there 
were no controls on the patient population. This may have 
resulted in unknown biases and skewed outcomes.
It should also be acknowledged that the lockdown 
restrictions associated with the COVID-19 pandemic may 
have impacted the PSOLife CARE Program as there was a 
noticeable decrease in the uptake of patients into the 
Program from February 2020, although patient satisfaction 
scores remained high from April 2020 to September 2020. 
Indeed, the COVID-19 pandemic was unlikely to have 
affected the patient satisfaction data linked to the PSP 
because patients could still be contacted through the 
remote contact center.
Conclusion
With improved adherence to secukinumab, both patients 
and physicians were satisfied by the PSOLife CARE 
Program. Ultimately, PSPs aim to enhance the benefits, 
value, and quality of patient care, improve treatment man-
agement, and increase long-term adherence to therapy. The 
benefits of PSPs can be observed for patients, caregivers, 
and medical professionals, and may bring about economic 
benefits to health care systems, such as the Italian National 
Health Services, attributable to decreased health care uti-
lization and costs for well-managed patients.
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